Masterclass: Axial spondyloarthritis for osteopaths and manual therapists

MacMillan, Andrew; Corser, Alex; Clark, Zoë; McCrum, Carol; Gaffney, Karl

doi:10.1016/j.ijosm.2021.03.005

Cited by 2 publications

(3 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the previous evaluation there has been increased professional profiling of clinical guidance, professional education strategies, conference presentations, social media and UK advocacy campaigns across professional areas to support greater awareness, recognition and referral of suspected axSpA (Barnett et al., 2020; Kiltz et al., 2020; MacMillan et al., 2021; National Axial Spondyloarthritis Society [NASS], (2020); van der Heijde et al., 2017; Webb et al., 2020).…”

Section: Introductionmentioning

confidence: 99%

A UK survey evaluation of First Contact Practitioners' and musculoskeletal physiotherapists' confidence, recognition, and referral of suspected axial spondyloarthritis

Steen

McCrum

Cairns

2022

Musculoskeletal Care

Self Cite

View full text Add to dashboard Cite

Background: Axial Spondyloarthritis is an inflammatory disease associated with significant diagnostic delays. Steen et al. (2021) found inadequate consideration of axial Spondyloarthritis (axSpA) in physiotherapists back pain assessments. Since the previous survey, increased professional education on axSpA has occurred and First Contact Practitioners (FCPs), now widely established in General Practice, are key in supporting earlier recognition. Objectives: (1) To re-evaluate physiotherapists' and evaluate FCPs' awareness, knowledge, and confidence in screening for and recognising features of axSpA and criteria prompting referral to rheumatology. (2) To compare these results to previous research (Steen et al., 2021). Design: As per Steen et al. (2021), an online survey was undertaken combining back pain vignettes (reflecting axSpA, non-specific low back pain [NSLBP] and radicular syndrome) and questioning on features of suspected axSpA. Results: 165 surveys were analysed. Only 73% (n = 120/165) of respondents recognised the axSpA vignette compared to NSLBP 91% (n = 80/88) and radicular syndrome 88% (n = 68/77). An improvement in axSpA recognition was demonstrated compared with previous data. FCPs performed slightly better with 77% (n = 67/87) of respondents recognising the axSpA vignette. Adequate awareness of national referral guidance was evident in only 55% of 'clinical reasoning' and 6% of 'further subjective screening' responses. There was still misplaced confidence in recognising clinical features of axSpA compared to knowledge levels shown, including high importance given to inflammatory markers. Conclusion(s):Musculoskeletal physiotherapists demonstrate some improved knowledge and awareness of axSpA compared with previous study findings.Consideration of axSpA is still not universal in musculoskeletal physiotherapists' or FCPs' approaches to persistent back pain assessments and awareness of national referral guidance remains limited. This study highlights the continued need for professional education. Enhanced knowledge of screening and referral criteriaThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

Section: Introductionmentioning

confidence: 99%

A UK survey evaluation of First Contact Practitioners' and musculoskeletal physiotherapists' confidence, recognition, and referral of suspected axial spondyloarthritis

Steen

McCrum

Cairns

2022

Musculoskeletal Care

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Spondyloarthritis (SpA) is a series of chronic inflammatory conditions that have a range of manifestations, including predominantly axial SpA (radiographic axial SpA [axSpA] and non-radiographic axial SpA) and peripheral SpA (enteropathic arthritis, reactive arthritis, and psoriatic arthritis). [ 1 ] People with predominantly axSpA may have additional peripheral symptoms, and vice versa. Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), or a combination of both, can usually ameliorate disease activity and retard joint damage, thereby improving the quality of life of patients with SpA.…”

Section: Introductionmentioning

confidence: 99%

Risk of infections of biological and targeted drugs in patients with spondyloarthritis: meta-analysis of randomized clinical trials

Man

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

Background: Concerns exist regarding the risk of infections in patients with spondyloarthritis (SpA) treated with biologics. We assessed the risk of infections of biological and targeted drugs in patients with SpA by performing a meta-analysis based on randomized controlled trials (RCTs). Methods: A systematic literature search was conducted in PubMed, Embase, Web of Science, the Cochrane Library, and China Biology Medicine Disc for RCTs evaluating the risk of infections of biological therapy in patients with SpA from inception through August 9, 2021. We calculated a pooled Peto odds ratio (OR) for infections in biologics-treated patients vs. placebo patients. The risk of bias on the included RCTs was assessed by using the Cochrane Risk of Bias Tool. Results: In total, 62 studies were included in this meta-analysis. Overall, the risk of infection (

show abstract

Masterclass: Axial spondyloarthritis for osteopaths and manual therapists

Cited by 2 publications

References 77 publications

A UK survey evaluation of First Contact Practitioners' and musculoskeletal physiotherapists' confidence, recognition, and referral of suspected axial spondyloarthritis

A UK survey evaluation of First Contact Practitioners' and musculoskeletal physiotherapists' confidence, recognition, and referral of suspected axial spondyloarthritis

Risk of infections of biological and targeted drugs in patients with spondyloarthritis: meta-analysis of randomized clinical trials

Contact Info

Product

Resources

About